Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

759 - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and Circulating Interluekin-6 (IL-6) as biomarker in Breast Cancer Patients

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Md Shah Jalalur Rahman Shahi

Citation

Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426

Authors

M.S.J.R. Shahi1, M. Dey2, A.K. Chowdhury2

Author affiliations

  • 1 Oncology, Ahsania Mission Cancer General Hospital, 1230 - Dhaka/BD
  • 2 Immunology, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka/BD
More

Resources

Abstract 759

Background

Breast cancer, the most commonly diagnosed non-cutaneous malignancy in women, is a multifactorial disease with important impact in immune system. Aberrant inflammatory marker, important feature of disease, which has role in both disease and prognosis. The most notably is interleukin-6 pathway which works as the link between inflammation and angiogenesis to malignancy. hs-CRP is a well-known surrogate marker for inflammation, with the newly found prognostic value to detect progression of malignancy.

Methods

This case control study contained two arms. Arm A includes 60 female patients with histologically proven breast cancer who were enrolled from the radiotherapy outpatient department (OPD) of DMCH with known clinical and pathological parameters. Arm B included 60 healthy age-matched females. Enzyme-Linked Immuno-Sorbent Assay (ELISA) was used to measure Serum levels of IL-6, and immunonephlometry was used to measure hs-CRP.

Results

Showed that statistically significant difference in Serum levels of IL‐6 among the samples of breast cancer patients compared to healthy control (p < 0.05) with breast cancer patient having higher values. Results also showed that statistically significant difference in Serum levels of hs-CRP among the samples of breast cancer patients compared to healthy control (p < 0.05) with breast cancer patient having higher values. Strong correlation was found between higher IL-6 levels and increasing tumor size, LN invasion and metastasis. Higher values of hs-CRP also showed strong correlation with larger tumor size, LN invasion and metastasis. An increasing trend of serum IL-6 and hs-CRP was found with higher TNM stage groups. Positive correlation between higher hs-CRP and IL‐6 levels (r2=0.585, p < 0.001) was found in the study. However, the study failed to show any significant correlation between higher IL-6 and hs-CRP value with regard to patient’s HER 2 receptor status(P = 0.616), and Steroid receptor status (ER, PR) (P = 0.676).

Conclusions

This study revealed higher IL-6 and hs-CRP levels with disease progression. Therefore IL-6 and hs-CRP levels have the potential to be used as prognostic biomarker for breast cancer patients.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Department of Immunology, BIRDEM.

Funding

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings